Summit Therapeutics is trading at $14.73 (-4.13%) amid biotech-sector weakness and broader market selling.
- The supplied data show XBI fell 2.06% during the regular session.
- The FDA has begun reviewing ivonescimab; coverage also reports the HARMONi trial did not achieve statistically significant overall-survival improvement.
- Neither report directly attributes the October 16 move to that news.